Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ontak in Adult T-Cell Leukemia
NCT00117845Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 2005
- Primary completion
- Dec 2011
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of denileukin diftitox in adult T-cell leukemia/lymphoma (ATLL), sponsored by National Cancer Institute. Primary endpoint: Overall Response Rate at 12 months. Started Jul 2005; status: terminated.
02
Drugs
denileukin diftitox
03
Conditions
adult T-cell leukemia/lymphoma (ATLL)
Beyond the preview
Go deeper on NCT00117845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00117845.